Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review

The efficacy of first-and second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients with the EGFR L861Q mutation has been studied previously. However, there is little evidence on the efficacy of osimertinib in NSCLC patients with uncommon mutations....

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ruiting, Chen, Ruilian, Chen, Zhiqiang, Hu, Leihao, Guo, Wei, Zhang, Zexin, Lin, Lizhu, Chen, Hanrui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445031/
https://www.ncbi.nlm.nih.gov/pubmed/34540698
http://dx.doi.org/10.3389/fonc.2021.731572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445031/
https://www.ncbi.nlm.nih.gov/pubmed/34540698
http://dx.doi.org/10.3389/fonc.2021.731572

Ejemplares similares